Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the General Meeting, held at the company’s headquarters in Paris, France on May 20, 2015, adopted all of the resolutions recommended by the Board of Directors.

Please be advised that the voting results of the Combined General Meeting are available on our website www.onxeo.com, in the section “Investors/General meetings”.

150520EN_Shareholders-meeting